Current clinical guidelines on the pharmacological management of severe dementia recommend the use of cholinesterase inhibitors in severe Alzheimer’s disease (AD) with more recent recommendations of the addition of memantine to anticholinesterase inhibitors for severe AD (O'Brien et al., 2017, Schmidt et al., 2015). This evidence concerns the gene BCHE and Alzheimer disease.